Skip to main
GBIO
GBIO logo

Generation Bio (GBIO) Stock Forecast & Price Target

Generation Bio (GBIO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Generation Bio Co is a genetics medicine company that aims to develop gene therapies targeting liver and retina-related diseases, utilizing its innovative siRNA/ctLNP delivery system and optimized iqDNA technology. The company is strategically focusing on validated T-cell mediated autoimmune indications, thereby mitigating risks linked to target selection, which positions it favorably against competition in this sector. Overall, the potential for positive clinical readouts from its technology platforms is believed to significantly enhance shareholder value, providing a strong basis for a positive outlook on the company’s financial prospects.

Bears say

Generation Bio Co faces significant risks regarding its ability to advance its preclinical assets into clinical studies, which could undermine its long-term growth potential and product pipeline. The repeated emphasis on the challenges of progressing these assets suggests a lack of confidence in the company's developmental capabilities, which may impact investor sentiment negatively. Additionally, the company's reliance on unproven technologies, such as its ctLNP delivery system and iqDNA platform, raises concerns about its prospects for successfully commercializing therapies for rare and untreated diseases.

Generation Bio (GBIO) has been analyzed by 3 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Generation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Generation Bio (GBIO) Forecast

Analysts have given Generation Bio (GBIO) a Buy based on their latest research and market trends.

According to 3 analysts, Generation Bio (GBIO) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Generation Bio (GBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.